Evommune (EVMN) Depreciation & Amortization (CF) (2024 - 2026)
Evommune (EVMN) posted quarterly Depreciation & Amortization (CF) of $349000.0 for Q1 2026, down 7.43% year-over-year from $377000.0 in Q1 2025, and up 7.06% quarter-over-quarter from $326000.0 in Q4 2025.
Evommune (EVMN) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $349000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 7.43% year-over-year to $349000.0; the TTM figure through Mar 2026 stood at $1.1 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, up 7.93% from the prior year.
- Depreciation & Amortization (CF) grew to $349000.0 in Q1 2026 per EVMN's latest filing, from $326000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $377000.0 in Q1 2025 and bottomed at $326000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $353000.0 across 3 years, with a median of $354500.0 in 2024.
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) decreased 9.44% — and 2026, when it slipped 7.43%.
- Evommune's Depreciation & Amortization (CF) stood at $360000.0 in 2024, then fell by 9.44% to $326000.0 in 2025, then gained by 7.06% to $349000.0 in 2026.
- Business Quant data shows EVMN's Depreciation & Amortization (CF) at $349000.0 in Q1 2026, $326000.0 in Q4 2025, and $377000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | 552,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 552,000.00 |
| Jun 30, 2026 | 552,000.00 |
| Mar 31, 2026 | 349,000.00 |
| Mar 31, 2026 | 349,000.00 |
| Dec 31, 2025 | 326,000.00 |
| Dec 31, 2025 | 326,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Mar 31, 2025 | 377,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Dec 31, 2024 | 360,000.00 |